Amar Sawhney, PhD, CEO, to present at the Ophthalmology Innovation
Summit @ AAO
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 14, 2014--
Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Amar
Sawhney, Ph.D., President and Chief Executive Officer, will present at
the Ophthalmology Innovation Summit (OIS) at AAO on October 16th,
2014 at 11:35 AM. Dr. Sawhney will also sit on the panel IPOs in
Ophthalmology – The Class of 2014 And Beyond at 4:10 PM. The
Ophthalmology Innovation Summit will take place at the Palmer House
Hilton in Chicago, IL.
Following the Ophthalmology Innovation Summit, Ocular Therapeutix will
exhibit at the American Academy of Ophthalmology (Booth #2770). In
addition, several ophthalmologists are scheduled to present data related
to Ocular Therapeutix’s products and pipeline, including the ReSure®
Sealant and its sustained release dexamethasone punctum plugs, during
the Annual Meeting.
About the Ophthalmology Innovation Summit
The Ophthalmology Innovation Summit (OIS) was created to facilitate
meaningful interactions and business partnerships between physicians,
entrepreneurs, investors and industry executives who are driving
ophthalmic innovation. OIS addresses key issues – both hurdles and
opportunities while showcasing the most promising private ophthalmic
companies. For more information, please visit www.ois.net.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix’s lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain, and
Phase 2 clinical development for glaucoma and allergic conjunctivitis.
The Company is also evaluating sustained-release injectable anti-VEGF
drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery. For more information, please visit www.ocutx.com.
Source: Ocular Therapeutix, Inc.
Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott
Corning
Vice President of Sales and Marketing
scorning@ocutx.com
